Feasibility of single use systems for flexible pDNA manufacture and improved service offering

Cell and gene therapy products are changing the lives of patients receiving treatment as part of clinical trials. Plasmid DNA represents a critical material required to enable the development and production of viral vectors to support both clinical trials and in-market supply for these innovative Gene Therapy products in order to treat patients. This project, lead by Cobra Biologics, aims to perform small scale feasibility studies utilising state of the art single-use technology and 3D printing to deliver critical process information requried to progress towards large scale plasmid DNA manufacturing in the UK. The project will support a larger investment by Cobra Biologics to enhance production capability, enabling retention of UK buisness and developing opportunities to move into new markets for clinical and commercial manufacture. Delivery of an enhanced manufacturing service offering will support existing and new customers' clinical and commercial ambitions, leading to more innovative Gene Therapy medicines reaching patients.